title: Targeted therapy in her2-positive metastatic breast cancer: a review of the literature.
abstract: Breast tumours positive for her2 (human epidermal growth factor receptor 2) represent approximately 20% of all breast cancer cases and are associated with an aggressive natural history. The advent of targeted anti-her2 therapies has dramatically improved disease control and survival in patients with metastatic her2-positive breast cancer. Targeted agents are now considered the standard of care in the first-line setting and beyond. The present review summarizes the currently available data on targeted anti-her2 therapies from completed randomized phase iii clinical trials and briefly discusses emerging advances that will address unmet needs in metastatic her2-positive breast cancer.
authors.affiliation: Department of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON.
authors.forename: X
authors.initials: X
authors.lastname: Zhu
authors.affiliation: Department of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON.
authors.forename: S
authors.initials: S
authors.lastname: Verma
keywords: her2; metastatic breast cancer; phase iii trials; targeted therapy
references.citation: Ann Oncol. 2006 Jun;17(6):935-44
references.pmid: 16603601
references.citation: J Clin Oncol. 2013 Jun 1;31(16):1947-53
references.pmid: 23509322
references.citation: J Clin Oncol. 2011 Jan 20;29(3):264-71
references.pmid: 21149659
references.citation: N Engl J Med. 2012 Nov 8;367(19):1783-91
references.pmid: 23020162
references.citation: J Clin Oncol. 2011 Jan 10;29(2):149-56
references.pmid: 21115860
references.citation: Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16
references.pmid: 16829981
references.citation: J Clin Oncol. 1993 Oct;11(10):1936-42
references.pmid: 8105035
references.citation: Oncogene. 1990 Jul;5(7):953-62
references.pmid: 1973830
references.citation: Breast Cancer Res Treat. 2008 Dec;112(3):533-43
references.pmid: 18188694
references.citation: Science. 1987 Jan 9;235(4785):177-82
references.pmid: 3798106
references.citation: J Clin Oncol. 2012 Jul 20;30(21):2585-92
references.pmid: 22689807
references.citation: Lancet Oncol. 2014 May;15(6):580-91
references.pmid: 24742739
references.citation: J Clin Oncol. 2009 Nov 1;27(31):5278-86
references.pmid: 19770385
references.citation: J Clin Oncol. 2006 Dec 20;24(36):5658-63
references.pmid: 17102066
references.citation: J Clin Oncol. 2006 Jun 20;24(18):2786-92
references.pmid: 16782917
references.citation: J Clin Oncol. 2009 Nov 20;27(33):5538-46
references.pmid: 19786658
references.citation: N Engl J Med. 2012 Jan 12;366(2):109-19
references.pmid: 22149875
references.citation: BMC Cancer. 2011 Jun 15;11:248
references.pmid: 21676217
references.citation: Breast Cancer Res Treat. 2013 Oct;141(3):507-14
references.pmid: 24104881
references.citation: Mol Cancer Ther. 2014 Nov;13(11):2618-29
references.pmid: 25189543
references.citation: Oncologist. 2009 Apr;14 (4):320-68
references.pmid: 19346299
references.citation: J Clin Oncol. 2010 Jul 10;28(20):3271-7
references.pmid: 20498394
references.citation: Oncologist. 2010;15(9):924-34
references.pmid: 20736298
references.citation: Cancer. 2007 Sep 1;110(5):965-72
references.pmid: 17614302
references.citation: J Clin Oncol. 2009 Nov 20;27(33):5529-37
references.pmid: 19786670
references.citation: Br J Clin Pharmacol. 2013 Aug;76(2):248-62
references.pmid: 23173552
references.citation: N Engl J Med. 2001 Mar 15;344(11):783-92
references.pmid: 11248153
references.citation: Annu Rev Med. 2013;64:15-29
references.pmid: 23043493
references.citation: J Clin Oncol. 2009 Apr 20;27(12):1999-2006
references.pmid: 19289619
references.citation: Lancet Oncol. 2013 Jan;14(1):64-71
references.pmid: 23122784
references.citation: J Clin Oncol. 2014 Nov 20;32(33):3753-61
references.pmid: 25332247
references.citation: J Clin Oncol. 2014 Jul 1;32(19):2078-99
references.pmid: 24799465
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1124-30
references.pmid: 20124187
references.citation: N Engl J Med. 2006 Dec 28;355(26):2733-43
references.pmid: 17192538
references.citation: J Clin Oncol. 2014 Jul 1;32(19):2100-8
references.pmid: 24799487
references.citation: Breast. 2012 Feb;21(1):27-33
references.pmid: 21862331